Medical imaging in the assessment of cardiovascular disease risk.
Journal
Current opinion in clinical nutrition and metabolic care
ISSN: 1473-6519
Titre abrégé: Curr Opin Clin Nutr Metab Care
Pays: England
ID NLM: 9804399
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
4
8
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
The prevalence of obesity has exponentially increased during the past years. The assessment of human adipose tissue distribution enables the identification of diverse ectopic adipose tissue depots, and helps to explain its relationship with cardiovascular health status. In this review, we summarize the current methods used in the assessment of human adipose tissue distribution, and we discuss the relationship between ectopic adipose tissue distribution and the risk of developing cardiovascular diseases and metabolic complications. The reference instruments to assess human adipose tissue distribution nowadays are the computed tomography and the magnetic resonance imaging (MRI). Today, MRI is the preferred imaging technique and enables the measurement of variations in the distribution of body adipose tissue among different phenotypes and individuals. This technique has helped to better understand the relationship between different ectopic adipose tissue depots and its relationship with cardiometabolic health among individuals. Although body composition can be assessed by simple techniques, these calculations can provide erroneous results and conclusions, requiring complex interpretations when diverse metabolic situations are concomitantly engaged. Contrarily, medical imaging techniques (e.g. MRI) enables to objectively and unbiasedly measure changes that may occur during longitudinal studies (e.g. pharmacological drug interventions).
Identifiants
pubmed: 37389461
doi: 10.1097/MCO.0000000000000960
pii: 00075197-990000000-00092
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
440-446Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Valenzuela PL, Carrera-Bastos P, Castillo-García A, et al. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol 2023; 20:475–494.
Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019; 7:715–725.
Chartrand DJ, Murphy-Després A, Alméras N, et al. Overweight, obesity, and CVD risk: a focus on visceral/ectopic fat. Curr Atheroscler Rep 2022; 24:185–195.
Sattar N, McMurray JJV, McInnes IB, et al. Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes Endocrinol 2023; 11:58–62.
Elsayed NA, Aleppo G, Aroda VR, et al. on behalf of the American Diabetes Association. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023. Diabetes Care 2023; 46: (Suppl 1): S128–S139.
Cao P, Song Y, Zhuang Z, et al. Obesity and COVID-19 in adult patients with diabetes. Diabetes 2021; 70:1061–1069.
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 2022; 29:5–115.
Agrawal S, Klarqvist MDR, Diamant N, et al. BMI-adjusted adipose tissue volumes exhibit depot-specific and divergent associations with cardiometabolic diseases. Nat Commun 2023; 14:266.
Pillay P, Lewington S, Taylor H, et al. Adiposity, body fat distribution, and risk of major stroke types among adults in the United Kingdom. JAMA Netw Open 2022; 5:E2246613.
Vilalta A, Gutiérrez JA, Chaves SZ, et al. Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH. Endocrinol diabetes Metab [Internet] 2022; 5:e00335.
Cadenas-Sanchez C, Idoate F, Cabeza R, et al. Effect of a multicomponent intervention on hepatic steatosis is partially mediated by the reduction of intermuscular abdominal adipose tissue in children with overweight or obesity: the EFIGRO Project. Diabetes Care 2022; 45:1953–1960.
Cadenas-Sanchez C, Cabeza R, Idoate F, et al. Effects of a family-based lifestyle intervention plus supervised exercise training on abdominal fat depots in children with overweight or obesity: a secondary analysis of a nonrandomized clinical trial. JAMA Netw Open 2022; 5:E2243864.
Shen W, Punyanitya M, Wang ZM, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004; 97:2333–2338.
Roblot V, Giret Y, Mezghani S, et al. Validation of a deep learning segmentation algorithm to quantify the skeletal muscle index and sarcopenia in metastatic renal carcinoma. Eur Radiol 2022; 32:4728–4737.
Lee SJ, Liu J, Yao J, et al. Fully automated segmentation and quantification of visceral and subcutaneous fat at abdominal CT: application to a longitudinal adult screening cohort. Br J Radiol [Internet] 2018; 91:20170968.
Faron A, Sprinkart AM, Kuetting DLR, et al. Body composition analysis using CT and MRI: intra-individual intermodal comparison of muscle mass and myosteatosis. Sci Rep 2020; 10:11765.
Klopfenstein BJ, Kim MS, Krisky CM, et al. Comparison of 3 T MRI and CT for the measurement of visceral and subcutaneous adipose tissue in humans. Br J Radiol 2012; 85:e826–e830.
Smith AC, Parrish TB, Abbott R, et al. Muscle-fat MRI: 1.5 Tesla and 3.0 Tesla versus histology. Muscle Nerve 2014; 50:170–176.
Ogawa M, Hashimoto Y, Mochizuki Y, et al. Effects of free weight and body mass-based resistance training on thigh muscle size, strength and intramuscular fat in healthy young and middle-aged individuals. Exp Physiol 2023; 1–11. [Epub ahead of print].
Díaz-Gómez JL, Mayo PH, Koenig SJ. Point-of-care ultrasonography. N Engl J Med [Internet] 2021; 385:1593–1602.
Price KL, Earthman CP. Update on body composition tools in clinical settings: computed tomography, ultrasound, and bioimpedance applications for assessment and monitoring. Eur J Clin Nutr 2019; 73:187–193.
Ceniccola GD, Castro MG, Piovacari SMF, et al. Current technologies in body composition assessment: advantages and disadvantages. Nutrition 2019; 62:25–31.
Sizoo D, de Heide LJM, Emous M, et al. Measuring muscle mass and strength in obesity: a review of various methods. Obes Surg 2021; 31:384–393.
Waddell T, Bagur A, Cunha D, et al. Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes. Obesity (Silver Spring) 2022; 30:1231–1238.
Tejani S, McCoy C, Ayers CR, et al. Cardiometabolic health outcomes associated with discordant visceral and liver fat phenotypes: insights from the Dallas Heart Study and UK Biobank. Mayo Clin Proc 2022; 97:225–237.
McPherson S, Armstrong MJ, Cobbold JF, et al. Quality standards for the management of nonalcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol 2022; 7:755–769.
Mann JP, Vreugdenhil AC, Zellos A, et al. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease. Lancet Gastroenterol Hepatol 2023; 8:P598–P600.
Quek J, Chan KE, Wong ZY, et al. Global prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8:20–30.
Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19:60–78.
Cohen CC, Harrall KK, Gilley SP, et al. Body composition trajectories from birth to 5 years and hepatic fat in early childhood. Am J Clin Nutr 2022; 116:1010–1018.
Jones GS, Graubard BI, Alvarez CS, McGlynn KA. Prediction of nonalcoholic fatty liver disease using anthropometry and body fat measures by sex and race/ethnicity in the United States. Obesity (Silver Spring) 2022; 30:1760–1765.
Francque SMA, Dirinck E. NAFLD prevalence and severity in overweight and obese populations. Lancet Gastroenterol Hepatol 2023; 8:2–3.
Lembo E, Russo MF, Verrastro O, et al. Prevalence and predictors of nonalcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. Diabetes Metab 2022; 48:101363.
Saponaro C, Sabatini S, Gaggini M, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver Int 2022; 42:2418–2427.
Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022; 19:638–651.
Hædersdal S, Andersen A, Knop FK, et al. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol 2023; 19:321–335.
Ratziu V, Francque S, Sanyal A. Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 2022; 76:1263–1278.
Lu Z, Jiang Z, Tang J, et al. Functions and origins of cardiac fat. FEBS J 2023; 290:1705–1718.
Powell-Wiley TM, Poirier P, Burke LE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2021; 143:e984–e1010.
Wagner R, Eckstein SS, Yamazaki H, et al. Metabolic implications of pancreatic fat accumulation. Nat Rev Endocrinol 2022; 18:43–54.
Rugivarodom M, Geeratragool T, Pausawasdi N, et al. Fatty pancreas: linking pancreas pathophysiology to nonalcoholic fatty liver disease. J Clin Transl Hepatol 2022; 10:1229–1239.
Truong E, Pandol S, Jeon C. Uniting epidemiology and experimental models: pancreatic steatosis and pancreatic cancer. EBioMedicine 2022; 79:103996.
Linge J, Petersson M, Forsgren MF, et al. Adverse muscle composition predicts all-cause mortality in the UK Biobank Imaging Study. J Cachexia Sarcopenia Muscle 2021; 12:1513–1526.
Linge J, Nasr P, Sanyal AJ, et al. Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. JHEP reports Innov Hepatol 2022; 5:100663.
Goodpaster BH, Bergman BC, Brennan AM, et al. Intermuscular adipose tissue in metabolic disease. Nat Rev Endocrinol 2023; 19:285–298.
Sparks LM, Goodpaster BH, Bergman BC. The metabolic significance of intermuscular adipose tissue: is IMAT a friend or a foe to metabolic health? Diabetes 2021; 70:2457–2467.
Yu F, Fan Y, Sun H, et al. Intermuscular adipose tissue in type 2 diabetes mellitus: noninvasive quantitative imaging and clinical implications. Diabetes Res Clin Pract 2022; 187:109881.